Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOQBGP)

Drug Name
IRAK-1/4 inhibitor Drug Info
Synonyms
IRAK-1-4 Inhibitor I; 509093-47-4; IRAK-1/4 Inhibitor I; IRAK-1/4 Inhibitor; Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor; CHEMBL379787; N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole; N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide; N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitrobenzamide; IRAK-1-4InhibitorI; IRAK1/4 Inhibitor I; MLS006010636; SCHEMBL3600534; GTPL5990; CTK8E9833; DTXSID50475143; QTCFYQHZJIIHBS-UHFFFAOYSA-N; MolPort-028-617-757; HMS3263A20; HMS3229G05
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11983295
CAS Number
CAS 509093-47-4
TTD Drug ID
DMOQBGP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Renal carcinoma antigen NY-REN-64 (IRAK-4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GS-5718 DMRKU0L Rheumatoid arthritis FA20 Phase 2 [2]
Zabedosertib DMEZGWP Atopic dermatitis EA80 Phase 2 [3]
CA-4948 DMWV8C6 Lymphoma 2A80-2A86 Phase 1 [4]
BAY1834845 DM8V62T Psoriasis vulgaris EA90 Phase 1 [5]
AZD6793 DM5GRZV Inflammation 1A00-CA43.1 Phase 1 [6]
SAR444656 DMIF2OL Atopic dermatitis EA80 Phase 1 [7]
Pyrazolopyrimidine and thienopyrimidine amide derivative 1 DM6TB4Z N. A. N. A. Patented [8]
Pyrazolopyrimidine and thienopyrimidine amide derivative 2 DMFUNH4 N. A. N. A. Patented [8]
Indazoletriazolephenyl derivative 1 DMHJDU6 N. A. N. A. Patented [8]
Indazoletriazolephenyl derivative 2 DMWZLK6 N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting IL-1 receptor-associated kinase 1 (IRAK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pyrazolopyrimidine and thienopyrimidine amide derivative 1 DM6TB4Z N. A. N. A. Patented [8]
Pyrazolopyrimidine and thienopyrimidine amide derivative 2 DMFUNH4 N. A. N. A. Patented [8]
Indazoletriazolephenyl derivative 1 DMHJDU6 N. A. N. A. Patented [8]
Indazoletriazolephenyl derivative 2 DMWZLK6 N. A. N. A. Patented [8]
WO2012007375C1 DMOZATX Discovery agent N.A. Investigative [9]
WO2012007375C7 DMPI2MA Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
IL-1 receptor-associated kinase 1 (IRAK1) TTXAJWN IRAK1_HUMAN Inhibitor [1]
Renal carcinoma antigen NY-REN-64 (IRAK-4) TTKFVXR IRAK4_HUMAN Inhibitor [1]

References

1 Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5.
2 IRAK4 degrader to take on innate immunity. Nat Biotechnol. 2020 Nov;38(11):1221-1223.
3 Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed Pharmacother. 2022 Sep;153:113459.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of AstraZeneca
7 Clinical pipeline report, company report or official report of Sanofi
8 Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2042).